

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 31/135</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 95/03038</b> <b>(43) International Publication Date:</b> 2 February 1995 (02.02.95)
<b>(21) International Application Number:</b> PCT/US94/08192 <b>(22) International Filing Date:</b> 20 July 1994 (20.07.94) <b>(30) Priority Data:</b> 095,349 23 July 1993 (23.07.93) US <b>(71) Applicant:</b> RIBOGENE, INC. [US/US]; 21375 Cabot Boulevard, Hayward, CA 94545 (US). <b>(72) Inventors:</b> GOLDBERG, Arthur, H.; 652 Sand Hill Circle, Menlo Park, CA 94025 (US). LACHMAN, Leonard; 21375 Cabot Boulevard, Hayward, CA 94545 (US). <b>(74) Agents:</b> POISSANT, Brian, M. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		<b>(81) Designated States:</b> AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KG, KR, KZ, LK, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, UA, UZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TREATMENT OF TACHYARRHYTHMIAS OF SUPRAVENTRICULAR ORIGIN <b>(57) Abstract</b> <p>This invention relates to the treatment of tachyarrhythmias of supraventricular origin. This condition may safely be treated by nasal administration of a composition comprising propranolol dissolved in a pharmaceutically acceptable, aqueous-based carrier. A total dose of up to 20 mg of propranolol may be administered at one time.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## TREATMENT OF TACHYARRHYTHMIAS OF SUPRAVENTRICULAR ORIGIN

Field of the Invention

The present invention relates to a novel method for  
5 administering propranolol to treat supraventricular  
tachyarrhythmias.

Background Art

Numerous  $\beta$ -adrenergic blocking agents are known for the  
10 treatment of various forms of cardiac arrhythmias. It is  
additionally common to treat some, but not all types of  
supraventricular tachyarrhythmias, with a  $\beta$ -blocker such as  
propranolol.

Where  $\beta$ -adrenergic blocking agents are appropriate,  
15 substantial oral doses have conventionally been administered  
chronically in order to control these arrhythmias. A total  
dose of at least 80 mg per day and up to 1000 mg per day of  
propranolol, for example, has been recommended to control  
tachyarrhythmias. A part of this total dosage is usually  
20 taken every 4 to 8 hours. The primary objective of such  
therapy has been prophylactic -- i.e. to maintain a reasonable  
heart rate as opposed to converting the arrhythmia.

Recently, another approach has been followed for  
treatment of certain tachyarrhythmias. This approach is for  
25 acute treatment. It involves a carefully monitored,  
intravenous titration of a  $\beta$ -adrenergic blocking agent. The  
need for great care derives from the danger of a  $\beta$ -blockade  
from injected propranolol. A  $\beta$ -blocking agent which is not  
significantly diffused in the bloodstream -i.e. a bolus -- can  
30 drastically lower blood pressure and is capable of causing  
cardiac standstill on reaching the heart. As a result, this  
approach has been followed only under direct physician  
control, normally in a hospital setting.

This relatively new, acute treatment involves the  
35 sequential administration of a series of small increments of  
dilute  $\beta$ -blocker. The administration is performed very  
slowly; for example, on a metered basis of no more than 1 mg

of propranolol per minute. Each separate administration is normally followed by a hiatus of one or two minutes before the next. This technique also utilizes a comparatively minor total dose of  $\beta$ -adrenergic blocking agent, usually less than 5 10 mg of propranolol. Together, these factors minimize the bolus effect of the drug.

The nasal administration of  $\beta$ -adrenergic blocking agents has also been suggested as a general means for the treatment of cardiac problems. This technique, which involves 10 substitution of nasal for conventional oral or intravenous administration, is described in U.S. Patent Nos. 4,428,883 and 4,394,390 (the disclosures of which are incorporated hereby by reference). It specifically references treatment of arrhythmias. These patents, however, do not describe any 15 specific procedure or objective.

#### Summary of the Invention

It is an object of the present invention to provide a novel method for the administration of propranolol in order to 20 treat tachyarrhythmias of a supraventricular origin.

It is a further object of this invention to provide a safe method of treating such tachyarrhythmias; one capable of self-administration and which may be performed immediately and virtually anywhere.

25 It is also an object of this invention to utilize propranolol for treating such tachyarrhythmias on an essentially acute basis in order to minimize the side effects and potentially adverse consequences of such a drug.

These and other objects are achieved in accordance with 30 the present invention which comprises nasally administering a composition comprising propranolol dissolved in a pharmaceutically acceptable aqueous-based carrier, a total dose of up to 20 mg of propranolol being administered immediately to reduce heart rate.

35 In accordance with the prior art prophylactic procedure, it is customary to provide sufficient blocking agents to maintain an effective concentration in the blood stream over



an extended time. In contrast, the present invention permits a direct and less intrusive use of  $\beta$ -adrenergic blocking agent. Propranolol may be administered only as needed and in reduced dosage amount as compared to a prophylactic procedure.

- 5 As a consequence, occurrences of adverse drug reaction, overdosage and/or discontinuance reaction are markedly reduced.

As compared to the prior art procedure of acute administration, the present invention is even more surprising.

- 10 This method utilizes higher concentrations and greater dosages of propranolol administered more quickly than an intravenous administration. Notwithstanding these differences, the present invention is far safer.

#### 15 Detailed Description of the Invention

This invention provides an improved method for the treatment of limited types of cardiac arrhythmias. More specifically, this invention is directed towards those forms of tachyarrhythmias which are of a supraventricular origin.

- 20 These include atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia, persistent sinus tachycardia, persistent atrial extrasystoles and tachycardia due to thyrotoxicosis.

- In most instances, these forms of tachyarrhythmia are  
25 initiated by a disorder of impulse formation and/or propagation caused by atrial premature contractions, usually following a myocardial infraction. These particular forms of tachyarrhythmia are believed to result from disturbances at the atrioventricular node, as opposed to other conduction  
30 systems of the heart.

- The present invention involves the nasal administration of an immediate dose up to about 20 mg of propranolol for the treatment of supraventricular tachyarrhythmia. Preferably the dose is from 5 to 15 mg of propranolol. By "immediately" it  
35 is meant that all the drug is administered at essentially one time, instead of slowly or incrementally over a prolonged period.

Surprisingly, undesirable effects have not been encountered incident this nasal means of administration. Due to various unique factors of the nasal induction of propranolol, this method does not require medically trained  
5 personnel or special medical facilities. It has been discovered to be so safe that it can be self-administered by the patient

The term "propranolol", as utilized herein, encompasses any pharmaceutically acceptable form of this compound which is  
10 water-soluble. Preferably, the propranolol is present as a free base, ester or a salt, such as propranolol hydrochloride. In these forms, the propranolol is delivered with maximum speed into the blood stream and to the heart of a patient.

The amount of propranolol in the present compositions is  
15 normally substantial. Desirably these compositions contain at least 20 mg of propranolol per ml, more preferably from 30 to 70 mg per ml of solution. Notwithstanding the prompt impact of this highly concentrated dosage form, however, no bolus effect is encountered.

20 Administration of the propranolol is performed in a pharmaceutically-acceptable, aqueous-based nasal carrier. The nature of these carriers is particularly important to the successful treatment of supraventricular tachyarrhythmia. The propranolol must be solubilized in water for the reasons  
25 already pointed out.

The carrier may have any conventional form. Aqueous liquids, ointments and gels may all be used. For other examples, reference is made of the text entitled "REMINGTONS PHARMACEUTICAL SCIENCES", 14th edition, 1970 (which is  
30 incorporated herein by reference). Preferred carriers comprise at least 80%, more preferably 90 to 99%, water by total weight. In another preferred form, the carrier is sprayable. This further facilitates its administration.

The nasal compositions of the present invention may  
35 contain various additional or optional components to ensure optimum therapeutic effect. These include one or more buffers, preferably selected to ensure a pH of between about 4

and 8. A preservative, such as an anti-bactericide, is also desirable. A cytoprotective agent may be employed to reduce the tendency of propranolol to irritate the cells within the nose. Further, minor amounts (usually less than 10% by weight) of organic solvents such as glycol may be included to ensure solubilization of the propranolol.

Administration of the present nasal compositions may be performed by any means which coats the nostril(s) of the patient suffering from supraventricular tachyarrhythmia. Thus it can be administered as nose drops, spray or any other means known in the art. The composition is preferably provided in a metered pump aerosol. In this manner, precise dosage amounts which are normally from about 0.5 to 0.1 ml per spray can be self-administered.

Soon after administration, the effect of the present compositions becomes evident. Most apparent is the reduction of heart rate. During tachyarrhythmia, the heart rate is well over 100 beats per minute and commonly ranges between about 125 to 350 beats per minute in humans. After administration, this rate will slow until it stabilizes at a more normal rate, desirably between about 60 to 90 beats per minute.

An example of the present nasal compositions and their use is set forth below. It is to be understood, however, that this example is only illustrative. It should not be construed as limiting this invention, as there are numerous modifications which will be apparent to those of ordinary skill in the art.

### Example

A study was performed involving 24 patients having confirmed diagnoses of tachyarrhythmia of a supraventricular origin. These patients were divided into two groups in order to compare the results of intravenous and nasal administration of propranol using a double dummy design.

The two different groups of patients experiencing heart rates of about 160 beats per minute were treated as follows:

Group A: These patients were infused intravenously with a 1 mg/ml aqueous solution of propranolol hydrochloride on a three minute cycle of 1 ml over the first minute, followed by two minutes of waiting. The cycle was repeated up to seven times, administration being terminated when the patient's heart rate reached 80 beats per minute.

In addition to the foregoing, a single placebo spray of 0.1 ml of water was injected into each nostril of the patient at the onset of the intravenous administration of active drug.

Group B: Each patient received a 0.1 ml spray of an aqueous solution of propranolol hydrochloride in each nostril. The concentration of the solution was 50 mg propranolol per ml.

This nasal administration was followed by a placebo intravenous infusion performed in the same manner as described for Group A.

During the study, 20% of the patients of Group A suffered one or more moderately severe, cardiovascular events. These were primarily short-lived hypotension or bradycardia attributed to the propranolol. Even though the nasal administration involved much higher and more concentrated dosage levels, no such events occurred in patients of Group B. This emphasized the greater safety of nasal administration of propranolol for the acute treatment of tachyarrhythmia.

During and after the onset of dosing, the heart rates of both groups of patients were monitored. This data was then graphed against time for a six hour period. The heart rates of patients in both groups dropped significantly and reached approximately 80 to 90 beats per minute within less than two hours. Despite the differences in timing and total propranolol dosage, there was no statistical deviation between the resultant plots for intravenous and nasal forms of administration. Thus both the simple procedure used for nasal

administration and that for intravenous titration proved equally effective in reducing the rate of heart beat.

While the present invention has been described in terms of certain preferred embodiments, various modifications 5 including substitutions and omissions may be made in them without departing from its spirit. Accordingly, it is intended that the scope of the invention be limited solely in accordance with the following claims.

10

15

20

25

30

35

WHAT IS CLAIMED IS:

1. A method for the acute treatment of tachyarrhythmia of supraventricular origin comprising nasally administering to a patient a composition comprising propranolol dissolved in a  
5 pharmaceutically acceptable aqueous-based carrier, a total dose of up to 20 mg of propranolol being administered immediately to reduce heart rate.
2. The method of Claim 1, wherein the composition contains at least 20 mg propranolol per ml of solution.
- 10 3. The method of Claim 1, wherein the total dose of propranolol is from 5 to 15 mg.
4. The method of Claim 3, wherein the composition comprises at least 80% of water by weight.
5. The method of Claim 4, wherein the composition is  
15 administered as a spray.
6. The method of Claim 4, wherein the composition is self-administered.
7. The method of Claim 6, wherein the propranolol is in the form of propranolol hydrochloride.
- 20 8. The method of Claim 7, wherein the composition is administered as a spray.
9. The method of Claim 6, wherein the tachyarrhythmia treated is atrial fibrillation.
10. The method of Claim 6, wherein the tachyarrhythmia  
25 treated is atrial flutter.
11. The method of Claim 6, wherein the tachyarrhythmia treated is paroxysmal supraventricular tachycardia.
12. The method of claim 6, wherein the tachyarrhythmia treated is persistent sinus tachycardia.
- 30 13. The method of Claim 6, wherein the tachyarrhythmia treated is due to thyrotoxicosis.
14. The method of Claim 6, wherein the tachyarrhythmia is due to persistent atrial extrasystoles.
15. The method of claim 1 which further comprises  
35 administering the composition to a patient who is experiencing a tachyarrhythmia of supraventricular origin which causes the

heart to beat at a heart rate of above about 100 beats per minute.

16. The method of claim 15 which further comprises administering the composition to a patient experiencing a  
5 tachyarrhythmia of supraventricular origin which causes a heart rate of about 125-350 beats per minute, said composition administered immediately so as to reduce the heart rate to about 60 to 90 beats per minute within about two hours.

10

15

20

25

30

35

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US94/08192

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61K 31/135

US CL : 514/652, 821

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/652, 821

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS, CAS ON-LINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 3,337,628 (CROWTHER ET AL.) 22 August 1967, see the entire document.	1-16
X	US, A, 4,394,390 (HUSSAIN ET AL.) 19 July 1983, column 5, lines 12 and 13.	1-16

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 SEPTEMBER 1994

Date of mailing of the international search report

SEP 27 1994

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

K. WEDDINGTON

Facsimile No. (703) 305-3230

Telephone No. (703) 308-1235